Anti–Epidermal Growth Factor Receptor Monotherapy in the Treatment of Metastatic Colorectal Cancer: Where Are We Today?
作者： Marc Peeters , Tim Price , Jean‐Luc Van Laethem
DOI: 10.1634/THEONCOLOGIST.2008-0167
关键词: Colorectal cancer 、 Internal medicine 、 Adverse effect 、 Oncology 、 Epidermal growth factor receptor 、 Panitumumab 、 Clinical trial 、 Medicine 、 Cetuximab 、 KRAS 、 Irinotecan
摘要: Over the past 10 years there has been a significant increase in armamentarium of agents available for use treatment advanced colorectal cancer (CRC). Among these new are two monoclonal antibodies targeting epidermal growth factor receptor (EGFR): cetuximab, mouse-human chimeric antibody, and panitumumab, fully human antibody. Both approved as monotherapy chemotherapy-refractory CRC. Cetuximab is also indicated combination with irinotecan. Here, we review reports phase II III clinical studies patients treated panitumumab or cetuximab monotherapy. The trials demonstrate similar efficacy profiles CRC monotherapy, some differences their adverse event profiles. In addition, recent results retrospective tumor KRAS gene mutational analyses anti-EGFR reviewed. Data from reviewed here clearly that an effective modality
ulb.ac.be
core.ac.uk
alphamedpress.org 参考文章(42)
X.-D. Yang, A. Jakobovits, Ping Wang, C. G. Davis, X.-C. Jia, J. R. F. Corvalan, Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Research. ,vol. 59, pp. 1236- 1243 ,(1999)
C. Bokemeyer, I. Bondarenko, J. T. Hartmann, F. G. De Braud, C. Volovat, J. Nippgen, C. Stroh, I. Celik, P. Koralewski, KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience Journal of Clinical Oncology. ,vol. 26, pp. 4000- 4000 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.4000
Eric Van Cutsem, Karen Geboes, The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer Best Practice & Research in Clinical Gastroenterology. ,vol. 21, pp. 1089- 1108 ,(2007) , 10.1016/J.BPG.2007.10.020
Angela B. Mariotto, K. Robin Yabroff, Eric J. Feuer, Roberta De Angelis, Martin Brown, Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000-2020 Cancer Causes & Control. ,vol. 17, pp. 1215- 1226 ,(2006) , 10.1007/S10552-006-0072-0
Yoshihiko Kawaguchi, Koji Kono, Kousaku Mimura, Hidemitsu Sugai, Hidenori Akaike, Hideki Fujii, Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. International Journal of Cancer. ,vol. 120, pp. 781- 787 ,(2007) , 10.1002/IJC.22370
P Martín-Martorell, S Roselló, E Rodríguez-Braun, I Chirivella, A Bosch, A Cervantes, Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. British Journal of Cancer. ,vol. 99, pp. 455- 458 ,(2008) , 10.1038/SJ.BJC.6604530
John Mendelsohn, Jose Baselga, The EGF receptor family as targets for cancer therapy. Oncogene. ,vol. 19, pp. 6550- 6565 ,(2000) , 10.1038/SJ.ONC.1204082
James Heun, Kyle Holen, Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. Clinical Colorectal Cancer. ,vol. 6, pp. 529- 531 ,(2007) , 10.3816/CCC.2007.N.019
Jeffrey A. Meyerhardt, Robert J. Mayer, Systemic Therapy for Colorectal Cancer The New England Journal of Medicine. ,vol. 352, pp. 476- 487 ,(2005) , 10.1056/NEJMRA040958
J. Randolph Hecht, Amita Patnaik, Jordan Berlin, Alan Venook, Imtiaz Malik, Simon Tchekmedyian, Lynn Navale, Rafael G. Amado, Neal J. Meropol, Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer Cancer. ,vol. 110, pp. 980- 988 ,(2007) , 10.1002/CNCR.22915